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The aim of the present study was to investigate the relationship between FEV1, pulse
oxymetri (SpO2) and blood gas status at rest with the arterial oxygen partial pressure
(PaO2) achieved during high altitude simulation test (HAST) in adult patients with
cystic ﬁbrosis. In addition, the PaO2 achieved during HAST (PaO2 HAST) was
compared with the corresponding values obtained during maximal exercise on the
treadmill.
Methods: Thirty patients (%= 20) with cystic ﬁbrosis, mean age 34 yrs (range
17−60), participated in the study. After base line measurements, they performed
HAST breathing 15% oxygen for 15 min in the sitting position. Arterial blood
gas measurements were obtained before and during HAST. In addition to HAST,
13 patients exercised until exhaustion on a treadmill for measuring of aerobic
capacity (VO2max) and PaO2.
Results: At rest, the mean (± SD) FEV1 was 59 (±25.06% of predicted, SpO2
94.9 (±1.92)%, and PaO2 10.2 (±1.23)kPa. During maximal exercise, VO2max
was 35.8 (±10.17) ml/min/kg and PaO2 11.0 (±4.95)kPa. The PaO2 HAST was
7.4 (±0.76)kPa at rest. Only ﬁve patients fulﬁlled the criteria for supplemental
oxygen during air travel based on BTS guidelines (PaO2< 6.6 kPa). The correlation
between FEV1, SpO2, and PaO2 at rest, as compared to PaO2 during HAST, was
poor (r = 0.3987, r = 0.210, r = 0375, respectively). However, there was a strong
correlation between PaO2 during maximal exercise and PaO2HAST (r = 0.84,
p = 0.0003).
Conclusions: In our study FEV1, SpO2 and PaO2 at rest seem to be of little value
for predicting the need of supplemental oxygen during air travel. On the other hand,
there is strong correlation between PaO2 during a simulated air travel and PaO2
during maximal exercise on a treadmill.
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Cystic ﬁbrosis is characterised by progressive decline in percentage predicted FEV1
(ppFEV1): the rate of decline is a predictor of risk of death and has been used
in clinical trials and timing of referral for lung transplantation. However, acute
infection or inﬂammation produces ﬂuctuations of FEV1, but their value in long
term prediction has not been studied.
We looked at prebronchodilator FEV1 results in 50 CF patients (mean age 30 years
[range 22−62], 21 male) to determine changes in annual variability and ppFEV1
between 2004 and 2008. The annual variability was deﬁned as the difference
between the highest and lowest ppFEV1 for that year.
The mean (SE) change in annual variability of ppFEV1 and best annual ppFEV1
in all patients (slope of regression line) was +0.48% (0.45) and −1.65% (0.96)
respectively. No trend was noted with annual variability of ppFEV1 (p = 0.28) in
contrast to the declining trend observed with best ppFEV1 (p = 0.09). A signiﬁ-
cant correlation was found between annual best ppFEV1 and ppFEV1 variability
(p = 0.007).
ppFEV1 variability was greater with Pseudomonas aeruginosa infection (p = 0.03)
and diabetes (p = 0.01).
We conclude that the annual variability of ppFEV1 (mean 15.0%, range
13.3−16.2%) in our patients over the study period is relatively preserved compared
with the pattern of decline in best ppFEV1. ppFEV1 variability appears not to be
a good measure of progressive lung disease but could signify asthmatic component
or exacerbation in cystic ﬁbrosis patients.
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Background: Most CF patients will die from lung disease of which FEV1 remains
the single most useful marker over the whole course. Recent data estimate currently
acceptable average FEV1 decline of 1−2% predicted/year. This rate is expected to
be lower in clinics starting from poor baseline values.
Methods: Our CF speciﬁc database was used to collect the data. Out of 166 patients
attending the clinic in 2008, regular and reliable spirometry data were available for
at least 4 years in 100 patients 10 y (Group A) and at least 8 years in 67 patients
14 y (Group B). The best FEV1 for each trimester was used to calculate the mean
annual FEV1 decline over the 4 and 8 y periods (linear regression).
Results: At the end of 2008, 166 patients had attended the clinic on a very regular
basis (at least every 10 weeks in all but 5), with spirometry being performed at
each visit as soon as possible (M: 51.8%, DF508/ DF508: 47%, >18 y: 49.4%,
mean FEV1 at the last visit of 2008: 100.5±13.9% pred. in 6 patients <18 y and
75.2±23.1% pred in adults, chronic colonization by PA: 18.6%). Over the 8 y period
between 2001 and 2008, 3 patients died (all in 2001) and 5 (4 alive) beneﬁted from
a lung transplant (2 in the last 4 years period). The mean (± SD) annual FEV1
actually improved over the past 4 years (+0.34% ± 2.67% in Group A) as well as
over the past 8 years (+ 0.40% ± 1.37 in group B).
Conclusion: Even in centres with high FEV1 values, FEV1 decline might be low
and actually “negative” (improvement over time) over a 8 years period. Assessing
novel therapies using this meaningful index might prove difﬁcult inasmuch as there
is an obvious need to standardize the way of calculating it.
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Objective: In CF bone loss is caused by various reasons, such as malnutrition, lower
sex hormones, inactivity and chronic inﬂammation. In literature the prevalence of
osteoporosis is about 30% and compression fractures is 7−35% in adult CF. Only
an early and adequate osteoporosis therapy (biphosponate/calcium/vitD therapy) in
osteopenic or osteoporotic CF can prevent them from bone fractures.
Methods and Results: In a prospective study we analysed bone radiographs
and dual-energy X-ray absorptiometries (DXA) of 15 CF patients (9f/6m; age:
29.7±10.2 yrs, range: 16−44 yrs; BMI: 16.9±2.15), who were lung transplanted
between 07/07−01/09 (CFTX).
Time CFTX to DXA was 21.3±13.1 days (range: 6−46). 9 CF (60%) had osteo-
porosis (T: −3.1±0.6), 4 CF (33.3%) had osteopenia (T: −1.82±0.43) and only
1 CF (6.7%) had normal perioperative bone mass density values. Hypercyphosis
and scoliosis was detected in 12 pts (80%). None of the CF had bone fractures in
the x ray.
Conclusion: The prevalence of osteoporosis and osteopenia in CF admitted to lung
transplantation (LUTX) is very high. A high bone fracture rate especially, if these
patients are exposed to corticoids and immunosuppressive therapy can be expected
in the ﬁrst postoperative year. We therefore conclude that:
1. All CF should be screened for osteoporosis.
2. A biphosponate/calcium/vitD therapy in CF with osteopenia or osteoporosis
before LuTX and thereafter, in combination with physical activity and optimal
nutrition may reduce the high incidence of osteoporosis and vertebral column
fractures within the ﬁrst year after LuTX.
